Functional Neuroimaging of Alcoholism Vulnerability (PIT) (CTNA)
Healthy
About this trial
This is an interventional treatment trial for Healthy focused on measuring Reward Circuitry, Impulsivity, Family History of Alcoholism, NMDA/DA Interactions
Eligibility Criteria
Inclusion Criteria:
- Biological father with a history of Alcoholism
- A least 1 other first- or second-degree relative with a history of Alcoholism.
Exclusion Criteria:
- Cannot be an only child
- A diagnosis of DSM-IV-TR Axis I psychotic disorders screened with the Mini International Neuropsychiatric Interview (MINI), done in the BARCS study (with the exception of Alcohol Abuse)
- Report of psychotic disorder in a 1º relative
- Prenatal exposure to alcohol (mother reported to drink 3 or more drinks on an occasion or more than 3 times per month during pregnancy
- Not speaking English fluently or being a non-native English speaker, or being educated in a primary language other than English >grade 1
- Mental retardation (Full Scale IQ<70)
- Traumatic brain injury with loss of consciousness > 30 minutes or concussion in last 30 days
- Presence or history of any medical/neurologic illness that may affect brain physiology (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural MRI (all structural scans are read by a licensed radiologist)
- Current pregnancy (all females will be tested with urine screens on the day of MRI)
- Any positive alcohol screen will result in exclusion
- Inability to comprehend the consent form appropriately
- Other specific fMRI exclusions include metal devices, clips or fragments in body (orbital x-ray performed if needed)
- Female participants under 125 pounds will be excluded from participating due to the strength and side effects in this segment of the population.
Sites / Locations
- Olin Neuropsychiatry Research Center at the Institute of Living, Hartford Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Family history positive, Memantine first, then placebo
Family history positive, placebo first, then Memantine
Family history negative, Memantine first, then placebo
Family history negative, placebo first, then Memantine
Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.